Nivolumab/Ipilimumab Approved for Hepatocellular Carcinoma

​The FDA has granted accelerated approval to the combination of nivolumab (Opdivo®, Bristol-Myers Squibb) and ipilimumab (Yervoy®, Bristol-Myers Squibb) for the treatment of patients with hepatocellular carcinoma following treatment with sorafenib.Safety and efficacy were evaluated in Cohort 4 of the phase 1/2 CHECKMATE-040 trial (NCT01658878), in which patients previously treated with sorafenib were randomized to receive either nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every three weeks for fou...
Continue reading

Baseline Liver Function As a Prognostic Factor in Unresectable HCC: Arndt Vogel, MD

In the phase 3 REFLECT trial, lenvatinib, an oral multikinase inhibitor, showed non-inferior survival compared with sorafenib in patients with untreated, unresectable hepatocellular carcinoma (HCC). However, the assessment of baseline liver function as a prognostic factor for patients with unresectable HCC receiving lenvatinib had not yet been investigated. In a post hoc analysis of the trial, a team of researchers led by Arndt Vogel, MD, Professor of Gastrointestinal Oncology at Hannover Medica...
Continue reading

In Advanced Hepatocellular Carcinoma, Nivolumab Superior for Quality of Life

​In advanced hepatocellular carcinoma (HCC), nivolumab (Opdivo®, Bristol-Meyers Squibb) is superior to sorafenib (Nexavar®, Bayer) with regard to health-related quality of life (HRQOL), according to results of the phase 3 CheckMate 459 trial to be reported on Friday at the 2020 Gastrointestinal Cancers Symposium.For CheckMate 459, 743 patients with advanced HCC were randomized in a 1:1 ratio to receive nivolumab or sorafenib. The researchers reported in September at the 44th European Society for...
Continue reading

Floxuridine Plus Gemcitabine and Oxaliplatin: Promising Results for Unresectable IHC

With a median overall survival of only 11 months, intrahepatic cholangiocarcinoma (IHC) warrants more effective therapies. Researchers recently discovered that a regimen of hepatic arterial infusion of floxuridine plus systemic gemcitabine and oxaliplatin produces promising outcomes in patients with unresectable IHC.In this phase 2 clinical trial, 38 patients with histologically confirmed, unresectable IHC were enrolled and treated. Participants with resectable metastatic disease to regional lym...
Continue reading

Aspirin and Biliary Tract Cancer Survival: Sarah Jackson, PhD

​Biliary tract cancers have a dismal prognosis, with five-year survival rates ranging from 5% to 15%. In their publication in JAMA Oncology, Sarah S. Jackson, PhD, and colleagues report that aspirin increases survival in biliary tract cancers, including gallbladder cancer, cholangiocarcinoma, ampulla of Vater cancer, and overlapping lesions of the biliary tract. In this interview with i3 Health, Dr. Jackson discusses the potential ramifications of her study's findings.What led you to pursue this...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.